Discover how the 2025 Nobel Prize in Medicine for Treg and FOXP3 research is revolutionizing treatments for autoimmunity, cancer, and transplants.



The 2025 Nobel Prize in Medicine – What Benefits Will Our Patients Gain?


Adrian Hunis, MD
School of Medicine, University of Buenos Aires (UBA)
Esta dirección de correo electrónico está siendo protegida contra los robots de spam. Necesita tener JavaScript habilitado para poder verlo.

Shimon Sakaguchi 
Osaka University,
Osaka, Japan

Fred Ramsdell
Sonoma Biotherapeutics,
San Francisco, USA

Mary E. Brunkow
Institute for Systems Biology,
Seattle, USA 

 



Abstract

In 2025, Mary E. Brunkow, Fred J. Ramsdell, and Shimon Sakaguchi received the Nobel Prize in Physiology or Medicine for fundamental discoveries in peripheral immune tolerance: the identification of regulatory T cells (Treg) and the pivotal role of the FOXP3 transcription factor in their identity and function. These findings explain how the immune system avoids self-damage while preserving defense capabilities, offering therapeutic opportunities in autoimmunity, transplantation, and oncology.

 

Introduction

Since its inception in 1901, the Nobel Prize in Physiology or Medicine, awarded by the Nobel Assembly at the Karolinska Institute, has honored discoveries that advance the health and welfare of humankind. The 2025 award continues this tradition, recognizing milestones in immunology that span from phagocytosis and the MHC to innate immunity and immune checkpoints. The discovery of Treg and FOXP3 represents a paradigm shift in understanding immune tolerance and its therapeutic translation.

 

Profiles of the Laureates


Shimon Sakaguchi (Japan): In 1995, he identified a CD4+CD25+ T cell subpopulation with regulatory function maintaining self-tolerance, and linked FOXP3 to Treg lineage commitment, establishing the field of peripheral tolerance.

Mary E. Brunkow (USA): In 2001, she linked mutations of the Foxp3 (scurfy) gene to lethal autoimmunity in mice, providing the genetic foundation for Treg function and the human correlation with IPEX syndrome.

Fred J. Ramsdell (USA): Co-discoverer of FOXP3’s essential role in immune homeostasis and Treg biology, with translational leadership toward Treg-based therapies.

 

Results and Mechanistic Insights

Regulatory T cells (CD4+CD25+FOXP3+) suppress effector immune responses through diverse mechanisms: competitive IL‑2 consumption (via high CD25 expression), secretion of immunoregulatory cytokines (IL‑10, TGF‑β, IL‑35), cell–cell contact (CTLA‑4, TIGIT, PD‑1), metabolic control (CD39/CD73→adenosine), targeted cytotoxicity, and reprogramming of antigen-presenting cells. Defective number or function of Treg leads to autoimmunity, while FOXP3 mutations cause IPEX syndrome.

 

Table 1. Mechanisms of Action of Treg and Pharmacological Targets

Mechanism Molecules Involved Potential Interventions
IL‑2 competition CD25 (IL‑2Rα) Low-dose IL‑2 / engineered IL‑2
Regulatory cytokines IL‑10, TGF‑β, IL‑35 Agonists / local induction
Inhibitory contact CTLA‑4, TIGIT, PD‑1 Modulatory antibodies, ligands
ATP metabolism CD39/CD73 → adenosine Purinergic modulators
Selective cytotoxicity Granzymes / perforin Tissue optimization
APC reprogramming ↓CD80/CD86, ↑IDO APC tolerization
 

 

Clinical and Therapeutic Implications

 

Table 2. Diseases Associated with Treg Dysfunction and Therapeutic Rationale

Disease

  Treg Role

Preferred Strategy

Autoimmune diseases (SLE, MS, T1D, IBD)

Functional/numerical deficit; unstable Treg

Expand/transfer Treg; IL‑2 bias

Solid organ / HCT transplant (GvHD)

Insufficient graft regulation

Adoptive Treg; induced tolerance

Cancer

Excess intratumoral Treg suppresses immunity

 Selective depletion/reprogramming + ICI

Chronic allergy

Defective allergen tolerance

Antigen-specific Treg induction

Chronic infections

Suppressed antiviral/antimicrobial response

 Fine balance; avoid excessive immunosuppression

 

 

Table 3. Treg-Based Therapeutic Modalities and Development Status

Modality Target Main Indications Status
Low-dose IL‑2 / muteins Expand Treg (CD25 high) SLE, MS, RA, IBD Phase I/II in several trials 
Autologous adoptive Treg Restore regulation Transplant, GvHD, autoimmunity Feasibility demonstrated, Phase I/II 
Selective anti‑CCR4/CCR8 Deplete intratumoral Treg Immunogenic solid tumors Early trials 
Selective anti‑CD25 (Teff-sparing) Deplete Treg, preserve Teff Oncology Preclinical / Phase I
Epigenetic/metabolic modulation Stabilize FOXP3/function Various Preclinical / early 

 

Future Perspectives

Future priorities include antigen-specific Treg engineering, biomarker development (FOXP3 TSDR, in vivo tracers), scalable ATMP manufacturing, rational combinations with ICI/JAK inhibitors, characterization of tissue and CD8+ Treg subsets, patient stratification, and long-term safety assessment.

 

Conclusions

The 2025 Nobel Prize in Medicine recognizes a paradigm shift: peripheral tolerance mediated by Treg/FOXP3 as a cornerstone of immune homeostasis. Therapeutic translation through IL‑2 bias, adoptive Treg transfer, and selective modulators already demonstrates efficacy signals in autoimmunity and transplantation, and emerging oncology strategies to modulate Treg contextually. Clinical consolidation will depend on robust biomarkers and indication-specific designs.

 

References


1. NobelPrize.org. The Nobel Prize in Physiology or Medicine 2025 – Press Release. 2025 Oct 6.
2. NobelPrize.org. Scientific Background to the Nobel Prize in Physiology or Medicine 2025. 2025.
3. Brunkow ME, et al. Nat Genet. 2001;27(1):68–73.
4. Sakaguchi S, et al. J Immunol. 1995;155(3):1151–64.
5. NobelPrize.org. Popular Information: They Understood How the Immune System is Kept in Check. 2025.
6. Sakaguchi S. Curr Opin Immunol. 2007;19(6):667–73.
7. Bennett CL, et al. Nat Genet. 2001;27(1):20–1.
8. Rudensky AY, et al. Nat Rev Immunol. 2011;11(11):845–52.
9. UCLA Health Newsroom. Fred Ramsdell wins 2025 Nobel Prize in Physiology or Medicine. 2025 Oct 6.
10. Shan F, et al. Cancers (Basel). 2022;14(19):4660.
11. Rosenzwajg M, et al. Ann Med. 2019;51(2):133–44.

BLOG COMMENTS POWERED BY DISQUS